Conference Coverage
Latest News
Oct 12, 2026 | Opinion
When surgery may be needed for prolonged ischemic priapism
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
Oct 12, 2026
ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC
Oct 12, 2026
FDA grants 510(k) clearance to OpenFlo urinary catheter
Oct 09, 2026
How can urologists separate personalized medicine from marketing?
Oct 09, 2026
Advertisement
Shorts
1:12
Belzutifan plus lenvatinib offers a new option after IO in ccRCC
3 days ago
by
Mina M. Fam, MD
1:01
Decipher score may help guide short-term ADT use
4 days ago
by
Angela Jia, MD, PhD
1:05
Cost-effectiveness model favors beta-3 agonists for OAB
5 days ago
by
Anjali Kapur, MD
1:21
New treatment options complicate BCG-unresponsive NMIBC care
6 days ago
by
Adam B. Weiner, MD(+1 more)
1:29
Why female sexual health is often overlooked in bladder cancer care
7 days ago
by
Armine K. Smith, MD
1:07
How APPs can expand access to clinical trials
12 days ago
by
Mary Dunn, MSN, RN, NP-C, OCN
0:28
What policymakers must do to preserve patient choice
13 days ago
by
Celeste Kirschner, CAE, MHSA
1:14
Why the bladder diary matters in nocturia workup
14 days ago
by
Kari A.O. Tikkinen, MD, PhD
0:50
3 actionable steps to improve PSMA-PET access
17 days ago
by
Juan Gómez Rivas, MD, FEBU, PhD
0:23
Site-neutral payment and the future of community urology
18 days ago
by
Celeste Kirschner, CAE, MHSA
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Advertisement
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
Advertisement
Advertisement
Trending on Urology Times
1
Variation in PSMA PET Adoption for Prostate Cancer Care
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
FDA grants fast track designation to VIR-5500 for mCRPC
4
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
5